Delta 9 Announces Q2 Fiscal 2018 Results
277 Per Cent YOY Growth with Continued Expansion and Diversification
WINNIPEG, Aug. 29, 2018 /CNW/ – DELTA 9 CANNABIS INC. (TSXV:NINE) (“Delta 9” or the “Company”) today announced its financial and operational results for the second quarter of fiscal 2018, ended June 30, 2018.
- Revenues of $715,746 and $1,047,853 – up 277% and 210% respectively – for the 3 month and 6 month period ending June 30, 2018 versus the same period in the prior year
- Gross Profit of $663,440 and $866,135 – up 172% and 215% respectively – for the 3 month and 6 month period ending June 30, 2018, versus the same period in the prior year
- The Company made a $3,000,000 Investment to acquire 50 per cent of the 70,000 square foot Delta West cannabis production facility in Calgary, Alberta, which it operates in partnership with Westleaf Cannabis, primarily to supply the cannabis market in Alberta
- The Company signed a 2,300 kg supply agreement with the Manitoba Provincial Government
- The Company came to terms on a $12,000,000 credit facility with a Tier 1 Canadian chartered bank, providing Delta 9 with additional capital for operations and expansion. The closing of such credit facility remains subject to due diligence
- The Company signed a Memorandum of Understanding with US biotech firm Nanosphere Health Sciences ceding the Master License in Canada for Nanosphere’s patented delivery system for cannabis
- The Company is currently completing work necessary to acquire the European Union “Good Manufacturing Practices” (GMP) Certification in order to initiate exports of medical cannabis to Germany
- The Company executed its option to acquire the land on which its current facility is located, as well as neighbouring property, giving Delta 9 the capacity to expand to more than 2 million square feet
“This has been a pivotal period for Delta 9 as we prepare for full legalization of recreational cannabis in Canada,” said CEO John Arbuthnot. “From our perspective, the real race for primacy in the Canadian cannabis market begins on October 17, and for this reason, our focus has been to position our company for rapid growth in the post-legalization era. To this end, we acquired one of only four licenses for retail in our home province of Manitoba; invested in an expansion in Alberta and Saskatchewan through our partners at Westleaf; acquired the exclusive license for the cannabis delivery system developed by Nanosphere; and signed a major supply agreement with the Province of Manitoba.”
Arbuthnot says agreeing to the terms of a debt financing at favourable terms with a Tier 1 Chartered Bank was another important step in the Company’s development. “We were already well financed for our current phase of expansion, but this $12 million dollar financing allows us to expand readily into other areas, including our exports into Europe. Delta 9 is building a company that is both vertically and horizontally integrated, with a healthy footprint across Canada, and the ability to make inroads into the global market.”
Arbuthnot says the other major initiative for Delta 9 was to increase the Company’s access to the Canadian and global markets. “It’s not just a matter of how much cannabis you can produce. It’s also about how much you can sell, and market access is critical. Our moves to acquire supply agreements, to acquire retail licenses, to achieve Preferred Supplier status with Pharmasave, and to acquire an export partner in Germany will be key drivers of our post-legalization revenues. Additionally, we are now moving heavily into research and development with our partners at Nanosphere, developing new and advanced products that are unique in the industry for both the medical and recreational markets.”
Delta 9 continues to expand its production capacity in Winnipeg in a project that remains ahead of schedule and under budget. The Company anticipates that the $16 million expansion will see production capacity increase to 17,500 kilograms of cannabis per year by the end of 2019. The Company also acquired lands adjacent to its current property, giving Delta 9 the ability to increase capacity to more than 2 million square feet of production space.
Additionally, Delta 9 owns 50 per cent of the 70,000 square foot Delta West facility in Alberta, which is expected to provide an initial increase of 4,000 kilograms of cannabis to the Company’s annual production.
Financial review Q2 2018
A comprehensive discussion of Delta 9’s financials and operations are provided in the Company’s Management Discussion & Analysis and Financial Statements which have been filed on www.sedar.com.
About Delta 9 Cannabis Inc.
Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical marijuana pursuant to the ACMPR and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9’s shares trade on the TSX Venture Exchange under the symbol “NINE”.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer for Forward-Looking Information
Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company’s future business plans and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: (i) Delta 9’s expansion plans; (ii) Delta 9’s production of cannabis; (iii) the closing of Delta 9’s credit facility with a Tier 1 Canadian chartered bank; (iv) the legalization of recreational cannabis in Canada;; and (v) Delta 9’s research and development plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that Delta 9’s currently contemplated expansion and development plans may cease or otherwise change, Delta 9’s production of cannabis may be lower than expected, Delta 9 may not obtain the required approvals from Health Canada, demand for Delta 9’s products may be lower than anticipated, Delta 9’s cost to produce its grow pods may be higher than expected and all other risk factors set forth in the annual information form of Delta 9 dated May 31, 2018 which has been filed on SEDAR. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.
SOURCE Delta 9 Cannabis Inc.
For further information: Gary Symons, Director of Communications, firstname.lastname@example.org, 250.300.9352